Epizyme, Inc. – NASDAQ:EPZM

Epizyme stock price today

$1.46
-0.01
-0.68%
Financial Health
0
1
2
3
4
5
6
7
8
9

Epizyme stock price quarterly change

+214.30%
quarter

Epizyme stock price yearly change

-73.17%
year

Epizyme key metrics

Market Cap
N/A
Enterprise value
412.12M
P/E
-0.70
EV/Sales
7.77
EV/EBITDA
-2.31
Price/Sales
4.63
Price/Book
-12.10
PEG ratio
0.10
EPS
-1.76
Revenue
53.00M
EBITDA
-178.36M
Income
-213.71M
Revenue Q/Q
111.59%
Revenue Y/Y
62.69%
Profit margin
-391.89%
Oper. margin
-370.05%
Gross margin
75.57%
EBIT margin
-370.05%
EBITDA margin
-336.48%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Epizyme stock price history

Epizyme stock forecast

Epizyme financial statements

Epizyme, Inc. (NASDAQ:EPZM): Profit margin
Sep 2021 5.20M -65.83M -1265.8%
Dec 2021 11.58M -50.65M -437.29%
Mar 2022 8.69M -55.50M -638.28%
Jun 2022 27.52M -41.72M -151.57%
Epizyme, Inc. (NASDAQ:EPZM): Earnings per share (EPS)
2021-11-09 -0.45 -0.64
2022-03-01 -0.53 -0.49
2022-05-10 -0.35 -0.38
2022-08-09 -0.36 -0.21
Epizyme, Inc. (NASDAQ:EPZM): Debt to assets
Sep 2021 332271000 316.89M 95.37%
Dec 2021 289000000 309.68M 107.16%
Mar 2022 312186000 301.06M 96.44%
Jun 2022 264159000 284.44M 107.68%
Epizyme, Inc. (NASDAQ:EPZM): Cash Flow
Sep 2021 -42.64M 66.64M 20.35M
Dec 2021 -51.96M 18.18M 7.60M
Mar 2022 -59.19M -44.18M 82.46M
Jun 2022 -54.80M 48.71M -257K

Epizyme alternative data

Epizyme, Inc. (NASDAQ:EPZM): Employee count
Aug 2023 250
Sep 2023 250
Oct 2023 250
Nov 2023 250
Dec 2023 250
Jan 2024 250
Feb 2024 250
Mar 2024 250
Apr 2024 250
May 2024 250
Jun 2024 250
Jul 2024 250

Epizyme other data

100.00% +17.23%
of EPZM is owned by hedge funds
143.93M +59.08M
shares is hold by hedge funds

Epizyme, Inc. (NASDAQ:EPZM): Insider trades (number of shares)
Period Buy Sel
Dec 2021 0 1780
Jan 2022 22666667 2922
Feb 2022 0 7162
Apr 2022 0 2741
Transaction Date Insider Security Shares Price per share Total value Source
Option
KUTOK JEFFERY officer: Chief Sc.. Stock Option (Right to Buy) 380,000 $1.39 $528,200
Option
KUTOK JEFFERY officer: Chief Sc.. Common Stock, par value $0.0001 380,000 $1.39 $528,200
Option
BOGLE GRANT C. director, officer.. Stock Option (Right to Buy) 417,500 $1.41 $588,675
Option
BEAULIEU JOSEPH officer: Senior Vice President,..
Stock Option (Right to Buy) 300,000 $1.39 $417,000
Option
BEAULIEU JOSEPH officer: Senior Vice President,..
Common Stock, par value $0.0001 300,000 $1.39 $417,000
Option
AGARWAL SHEFALI other Stock Option (Right to Buy) 400,000 $1.39 $556,000
Option
AGARWAL SHEFALI other Stock Option (Right to Buy) 43,473 $1.39 $60,427
Option
AGARWAL SHEFALI other Stock Option (Right to Buy) 56,527 $1.39 $78,573
Option
AGARWAL SHEFALI other Common Stock, par value $0.0001 400,000 $1.39 $556,000
Option
BOGLE GRANT C. director, officer.. Common Stock, par value $0.0001 417,500 $1.41 $588,675
Patent
Application
Filling date: 23 May 2022 Issue date: 8 Sep 2022
Application
Filling date: 23 Dec 2021 Issue date: 1 Sep 2022
Application
Filling date: 29 Nov 2017 Issue date: 25 Aug 2022
Application
Filling date: 15 Nov 2021 Issue date: 28 Jul 2022
Application
Filling date: 23 Nov 2021 Issue date: 21 Jul 2022
Application
Filling date: 21 Dec 2021 Issue date: 14 Jul 2022
Grant
Filling date: 5 Aug 2020 Issue date: 28 Jun 2022
Application
Filling date: 9 Dec 2021 Issue date: 23 Jun 2022
Application
Filling date: 18 Nov 2021 Issue date: 9 Jun 2022
Application
Filling date: 1 Nov 2021 Issue date: 26 May 2022
Friday, 19 May 2023
globenewswire.com
Thursday, 18 May 2023
globenewswire.com
globenewswire.com
Friday, 12 August 2022
businesswire.com
Wednesday, 10 August 2022
Zacks Investment Research
Monday, 27 June 2022
The Motley Fool
Benzinga
Market Watch
Thursday, 9 June 2022
Zacks Investment Research
Wednesday, 11 May 2022
Zacks Investment Research
Tuesday, 10 May 2022
Seeking Alpha
Zacks Investment Research
Monday, 9 May 2022
Zacks Investment Research
Tuesday, 3 May 2022
Zacks Investment Research
Business Wire
Thursday, 31 March 2022
Zacks Investment Research
Wednesday, 16 March 2022
Zacks Investment Research
Wednesday, 2 March 2022
Zacks Investment Research
Tuesday, 1 March 2022
Seeking Alpha
Zacks Investment Research
Tuesday, 22 February 2022
Business Wire
Thursday, 17 February 2022
Zacks Investment Research
Thursday, 3 February 2022
The Motley Fool
Wednesday, 2 February 2022
PennyStocks
Tuesday, 1 February 2022
Zacks Investment Research
Friday, 28 January 2022
Zacks Investment Research
Thursday, 27 January 2022
The Motley Fool
Pulse2
Thursday, 2 December 2021
Business Wire
Wednesday, 24 November 2021
Seeking Alpha
  • What's the price of Epizyme stock today?

    One share of Epizyme stock can currently be purchased for approximately $1.46.

  • When is Epizyme's next earnings date?

    Unfortunately, Epizyme's (EPZM) next earnings date is currently unknown.

  • Does Epizyme pay dividends?

    No, Epizyme does not pay dividends.

  • What is Epizyme's stock symbol?

    Epizyme, Inc. is traded on the NASDAQ under the ticker symbol "EPZM".

  • What is Epizyme's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Epizyme?

    Shares of Epizyme can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Epizyme's key executives?

    Epizyme's management team includes the following people:

    • Dr. Shefali Agarwal M.D., MPH Executive Vice President and Chief Medical & Devel. Officer(age: 51, pay: $684,960)
    • Mr. Matthew E. Ros Advisor(age: 58, pay: $634,050)
    • Dr. Jeffery L. Kutok Chief Scientific Officer(age: 58, pay: $563,980)
    • Mr. Grant C. Bogle Pres, Chief Executive Officer, Principal Financial Officer & Director(age: 67, pay: $46,250)
  • How many employees does Epizyme have?

    As Jul 2024, Epizyme employs 250 workers.

  • When Epizyme went public?

    Epizyme, Inc. is publicly traded company for more then 12 years since IPO on 31 May 2013.

  • What is Epizyme's official website?

    The official website for Epizyme is epizyme.com.

  • Where are Epizyme's headquarters?

    Epizyme is headquartered at 400 Technology Sq Ste 4, Cambridge, MASSACHUSETTS.

  • How can i contact Epizyme?

    Epizyme's mailing address is 400 Technology Sq Ste 4, Cambridge, MASSACHUSETTS and company can be reached via phone at +1 617 229 5872.

Epizyme company profile:

Epizyme, Inc.

epizyme.com
Exchange:

NASDAQ

Full time employees:

250

Industry:

Biotechnology

Sector:

Healthcare

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..

400 Technology Sq Ste 4
Cambridge, MASSACHUSETTS 02139

CIK: 0001571498
ISIN: US29428V1044
CUSIP: 29428V104